Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RemeGen (REGMY) announced significant positive results from its Phase 3 clinical trial of disitamab vedotin (DV) in combination with PD-1 inhibitor toripalimab. The study, evaluating the treatment as a first-line therapy for HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC), successfully met its primary endpoints of progression-free survival (PFS) and overall survival (OS).
The trial, involving 484 patients across 74 sites in China, demonstrated statistically significant improvements in both PFS and OS compared to standard chemotherapy, regardless of cisplatin eligibility or HER2 expression levels. The treatment showed a manageable safety profile with tolerable adverse reactions. RemeGen plans to file a Biologic License Application (BLA) with China's NMPA, with detailed data to be presented at upcoming international conferences.
Positive
- Phase 3 trial successfully met both primary endpoints (PFS and OS)
- Treatment showed efficacy regardless of cisplatin eligibility or HER2 expression level
- Demonstrated manageable safety profile and tolerable adverse reactions
- Plans to file BLA with China's NMPA for regulatory approval
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RC48-C016 is a randomized, active-controlled, multi-center phase 3 clinical trial evaluating efficacy and safety of DV plus toripalimab versus gemcitabine in combination with cisplatin/carboplatin in systemic-treatment-naive patients with HER2-expressing (defined as IHC 1+, 2+ or 3+) la/mUC. The study was initiated in June 2022 and conducted in 74 sites across
The principal researcher of this study, Professor Guo Jun from Peking University Cancer Hospital, said: "Extremely exciting! We, once again, jointly witnessed a strong positive result of DV combined with toripalimab in the first-line treatment of advanced urothelial carcinoma. Regardless of whether the patients are suitable for cisplatin treatment and regardless of patients' HER2 expression status, DV combined with toripalimab significantly improved PFS and OS. This outstanding efficacy proves the success of the 'HER2-ADC + immunotherapy' combination treatment concept, and is also a major breakthrough in the global treatment of urothelial carcinoma. We look forward to the excellent performance of DV in subsequent studies which should provide better decision-making basis for clinicians, bring more benefits to patients, and reshape the global treatment landscape of urothelial carcinoma with the 'Chinese approach'."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.